相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting PRC2 for the treatment of cancer: an updated patent review (2016-2020)
Milly Dockerill et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction
Yiran Guo et al.
TRENDS IN GENETICS (2021)
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase
Sharan K. Bagal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression
Rohan Kalyan Rej et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer
Talha Anwar et al.
AMERICAN JOURNAL OF PATHOLOGY (2021)
The noncanonical role of EZH2 in cancer
Jinhua Huang et al.
CANCER SCIENCE (2021)
Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method
Kensuke Misawa et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2021)
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
Zhihao Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Polycomb-group proteins in the initiation and progression of cancer
Xiujuan Zhao et al.
JOURNAL OF GENETICS AND GENOMICS (2021)
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors
Chen Li et al.
CLINICAL EPIGENETICS (2021)
LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins
Bhavana Ramadas et al.
CHEMMEDCHEM (2021)
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Guoqiang Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction
Daohai Du et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders
Stefano Tomassi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The PROTACtable genome
Melanie Schneider et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Going beyond Polycomb: EZH2 functions in prostate cancer
Su H. Park et al.
ONCOGENE (2021)
Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseases
Yanbei Tu et al.
PHARMACOLOGICAL RESEARCH (2021)
Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
Ming He et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
Xin Li et al.
THERANOSTICS (2021)
Engaging chromatin: PRC2 structure meets function
Paul Chammas et al.
BRITISH JOURNAL OF CANCER (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations
Kongkai Zhu et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2020)
Discovery of a first-in-class EZH2 selective degrader
Anqi Ma et al.
NATURE CHEMICAL BIOLOGY (2020)
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
Hope S. Rugo et al.
ADVANCES IN THERAPY (2020)
Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective
Laura M. Luh et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair
Allyson E. Koyen et al.
ONCOGENE (2020)
EZH2: a novel target for cancer treatment
Ran Duan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development
Rohan Kalyan Rej et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Marie-Lisa Eich et al.
CANCER RESEARCH (2020)
Lysosome-targeting chimaeras for degradation of extracellular proteins
Steven M. Banik et al.
NATURE (2020)
PROTAC: A promising technology for cancer treatment
Xin Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer
M. Cynthia Martin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Jessie Hao-Ru Hsu et al.
CELL CHEMICAL BIOLOGY (2020)
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Frances Potjewyd et al.
CELL CHEMICAL BIOLOGY (2020)
Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators
Danishuddin et al.
DRUG DISCOVERY TODAY (2019)
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis
Yu Zhao et al.
EMBO JOURNAL (2019)
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Julian Puppe et al.
CLINICAL CANCER RESEARCH (2019)
Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation
Anne Laugesen et al.
MOLECULAR CELL (2019)
Polycomb repressive 2 complex-Molecular mechanisms of function
Valentina L. Kouznetsova et al.
PROTEIN SCIENCE (2019)
Emerging Roles for Polycomb-Group Proteins in Stem Cells and Cancer
Ho Lam Chan et al.
TRENDS IN BIOCHEMICAL SCIENCES (2019)
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
Kai-li Zhang et al.
ACTA PHARMACOLOGICA SINICA (2019)
EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness
Houda Tabbal et al.
BRITISH JOURNAL OF CANCER (2019)
EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia
Subazini Thankaswamy Kosalai et al.
EPIGENETICS (2019)
An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response
Hongping Dong et al.
CANCER RESEARCH (2019)
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A. Yap et al.
CLINICAL CANCER RESEARCH (2019)
Targeting epigenetic machinery: Emerging novel allosteric inhibitors
Fei Ye et al.
PHARMACOLOGY & THERAPEUTICS (2019)
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Katharine L. Diehl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
Daiki Takahashi et al.
MOLECULAR CELL (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Structure, mechanism, and regulation of polycomb-repressive complex 2
Lindsay E. Moritz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
Kwok-Ho Chan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter
Lu Gan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
Bayley A. Jones et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding
Siming Chen et al.
MOLECULAR CELL (2018)
Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin
Chul-Hwan Lee et al.
MOLECULAR CELL (2018)
Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes
Simon Poepsel et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Structures of human PRC2 with its cofactors AEBP2 and JARID2
Vignesh Kasinath et al.
SCIENCE (2018)
Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes
Simon Poepsel et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: Current developments in medicinal chemistry
Xiaoyun Lu et al.
MEDICINAL RESEARCH REVIEWS (2018)
WD40 Repeat Proteins: Signalling Scaffold with Diverse Functions
Buddhi Prakash Jain et al.
PROTEIN JOURNAL (2018)
Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds
Rossella Fioravanti et al.
CHEMICAL RECORD (2018)
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
Jung Kim et al.
CELL REPORTS (2018)
Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors
Mao-rong Zhu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Inhibitors of Protein Methyltransferases and Demethylases
H. Umit Kaniskan et al.
CHEMICAL REVIEWS (2018)
Polycomb repressive complex 2 in an autoinhibited state
Matthew Bratkowski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
Ying Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)
Chao-Yie Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase
Andreas Lingel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The Multiple Facets of PRC2 Alterations in Cancers
M. Wassef et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
Wei Qi et al.
NATURE CHEMICAL BIOLOGY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex
Yupeng He et al.
NATURE CHEMICAL BIOLOGY (2017)
TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation
J. Li et al.
ONCOGENE (2017)
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Sheng Yu Ku et al.
SCIENCE (2017)
Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2
Kimberly D. Barnash et al.
ACS COMBINATORIAL SCIENCE (2017)
Small-Molecule Modulation of Protein Homeostasis
George M. Burslem et al.
CHEMICAL REVIEWS (2017)
Structure of the PRC2 complex and application to drug discovery
Yi Shi et al.
ACTA PHARMACOLOGICA SINICA (2017)
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding
Michael L. Curtin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
V. Gibaja et al.
ONCOGENE (2016)
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Rishi G. Vaswani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2
Neil Justin et al.
NATURE COMMUNICATIONS (2016)
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
Haikuo Zhang et al.
CANCER DISCOVERY (2016)
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Itys Comet et al.
NATURE REVIEWS CANCER (2016)
Developmental Control of Polycomb Subunit Composition by GATA Factors Mediates a Switch to Non-Canonical Functions
Jian Xu et al.
MOLECULAR CELL (2015)
Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation
Serena Sanulli et al.
MOLECULAR CELL (2015)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
Lianying Jiao et al.
SCIENCE (2015)
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer
Huiming Chen et al.
ONCOTARGET (2015)
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
Theresa Baker et al.
ONCOTARGET (2015)
Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2
Xiangqian Kong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma
Shu-Bin Gao et al.
MOLECULAR CANCER RESEARCH (2014)
Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
Eunhee Kim et al.
CANCER CELL (2013)
Elements of the Polycomb Repressor SU(Z) 12 Needed for Histone H3-K27 Methylation, the Interface with E(Z), and In Vivo Function
Aswathy N. Rai et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
PAF and EZH2 Induce Wnt/β-Catenin Signaling Hyperactivation
Hae-Yun Jung et al.
MOLECULAR CELL (2013)
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer
Woojin Kim et al.
NATURE CHEMICAL BIOLOGY (2013)
Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations
Hong Wu et al.
PLOS ONE (2013)
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Peter W. Lewis et al.
SCIENCE (2013)
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
Teruyuki Sato et al.
SCIENTIFIC REPORTS (2013)
PRC2 directly methylates GATA4 and represses its transcriptional activity
Aibin He et al.
GENES & DEVELOPMENT (2012)
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms
T. Ueda et al.
LEUKEMIA (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Shuet Theng Lee et al.
MOLECULAR CELL (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins
Taavi K. Neklesa et al.
NATURE CHEMICAL BIOLOGY (2011)
Polycomb complexes act redundantly to repress genomic repeats and genes
Martin Leeb et al.
GENES & DEVELOPMENT (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)
Chao Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Biochemical mechanisms of gene regulation by polycomb group protein complexes
Juerg Mueller et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2009)
Role of the polycomb protein EED in the propagation of repressive histone marks
Raphael Margueron et al.
NATURE (2009)
Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study
Masahito Shimizu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Structural basis of EZH2 recognition by EED
Zhifu Han et al.
STRUCTURE (2007)
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells
Bin Shi et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
A Kuzmichev et al.
GENES & DEVELOPMENT (2002)
分享论文
